Comparative Pharmacology
Head-to-head clinical analysis: GLYCOPREP versus POLYETHYLENE GLYCOL 3350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCOPREP versus POLYETHYLENE GLYCOL 3350.
GLYCOPREP vs POLYETHYLENE GLYCOL 3350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a competitive antagonist of acetylcholine at muscarinic receptors, thereby inhibiting the effects of parasympathetic nervous system activation. It does not cross the blood-brain barrier significantly, producing peripheral anticholinergic effects.
Osmotic laxative. Polyethylene glycol 3350 is a non-absorbable polymer that retains water in the colon via hydrogen bonding, increasing stool water content and stimulating defecation.
Adults: 10 units subcutaneously 30 minutes before first meal of the day, then 5 units after each subsequent meal. Total daily dose should not exceed 30 units.
17 g (1 capful or packet) dissolved in 4–8 oz (120–240 mL) water, administered orally once daily for constipation; for colonoscopy preparation, 240 g (4 L of solution) ingested at 240 mL every 10–15 minutes.
None Documented
None Documented
Terminal half-life 1.5-2 hours in adults; prolonged in renal impairment (up to 10-12 hours in anuria).
Terminal elimination half-life is 1-2 hours in patients with normal renal function; prolonged in renal impairment, but clinical impact minimal due to primarily fecal elimination.
Primarily renal (90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <10%.
Renal: approximately 20% excreted unchanged; Fecal: approximately 80% eliminated unchanged in feces.
Category C
Category C
Osmotic Laxative
Osmotic Laxative